Cargando…

Financial toxicity in lung cancer

In the United States, lung cancer is the third most common cancer and the overall leading cause of cancer death. Due to advances in immunotherapy and targeted therapy, 5-year survival is increasing. The growing population of patients with lung cancer and cancer survivors highlights the importance of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boulanger, Mary, Mitchell, Carley, Zhong, Jeffrey, Hsu, Melinda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634168/ https://www.ncbi.nlm.nih.gov/pubmed/36338686 http://dx.doi.org/10.3389/fonc.2022.1004102

Ejemplares similares

Financial toxicity in patients with lung cancer: a scoping review protocol
por: Fu, Liang, et al.
Publicado: (2022)

Psychometric properties of self-reported financial toxicity measures in cancer survivors: a systematic review
por: Zhu, Zheng, et al.
Publicado: (2022)

Development and Validation of Subjective Financial Distress Questionnaire (SFDQ): A Patient Reported Outcome Measure for Assessment of Financial Toxicity Among Radiation Oncology Patients
por: Dar, Mukhtar Ahmad, et al.
Publicado: (2022)

Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol
por: Riva, Silvia, et al.
Publicado: (2019)

Toxicities of Immunotherapy for Small Cell Lung Cancer
por: Fu, Yang, et al.
Publicado: (2021)

Psychometric properties of self-reported financial toxicity measures in cancer survivors: a systematic review protocol using COSMIN methodology
por: Zhu, Zheng, et al.
Publicado: (2020)

Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
por: Son, Christine, et al.
Publicado: (2023)

Influence of Dexamethasone Premedication on Acute Lung Toxicity in Lung SBRT
por: Alite, Fiori, et al.
Publicado: (2022)

Assessment of self-reported financial toxicity among patients with nasopharyngeal carcinoma undergoing radiotherapy: A cross-sectional study in western China
por: Jiang, Hua, et al.
Publicado: (2022)

Reflections on the Financial Toxicity of Cancer: 10 Years Later
por: Zafar, S Yousuf, et al.
Publicado: (2023)

Role of Real-World Data in Assessing Cardiac Toxicity After Lung Cancer Radiotherapy
por: Abravan, Azadeh, et al.
Publicado: (2022)

Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity
por: Yan, Shu, et al.
Publicado: (2023)

Financial Toxicity
por: Nogueira, Luciana de Alcantara, et al.
Publicado: (2020)

Racial and Ethnic Differences in the Financial Consequences of Cancer-Related Employment Disruption
por: Biddell, Caitlin B., et al.
Publicado: (2021)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity
por: Staropoli, Nicoletta, et al.
Publicado: (2023)

Frailty and medical financial hardship among older adults with cancer in the United States
por: Lao, Jiahui, et al.
Publicado: (2023)

Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer
por: Honda, Kazunori, et al.
Publicado: (2019)

Financial Toxicity of Having Bladder Cancer
por: Messing, Edward M.
Publicado: (2018)

Extracellular Vesicles for the Treatment of Radiation-Induced Normal Tissue Toxicity in the Lung
por: Montay-Gruel, Pierre, et al.
Publicado: (2021)

Lung-heart toxicity in a randomized clinical trial of hypofractionated image guided radiation therapy for breast cancer
por: Van Parijs, Hilde, et al.
Publicado: (2023)

Assessment of Financial Toxicity Among Patients With Advanced Lung Cancer in Western China
por: Xu, Tianqi, et al.
Publicado: (2022)

Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors
por: Schindler, Hannah, et al.
Publicado: (2022)

Genetic Polymorphisms and Platinum-Based Chemotherapy-Induced Toxicities in Patients With Lung Cancer: A Systematic Review and Meta-Analysis
por: Liu, Wenhui, et al.
Publicado: (2020)

Using Liposomes to Alleviate the Toxicity of Chelerythrine, a Natural PKC Inhibitor, in Treating Non-Small Cell Lung Cancer
por: Wang, Jiahui, et al.
Publicado: (2021)

Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Sholklapper, Tamir N., et al.
Publicado: (2022)

Lung cancer treatment rates and the role of the lung cancer nurse specialist: a qualitative study
por: Tod, Angela Mary, et al.
Publicado: (2015)

Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer
por: He, Kewen, et al.
Publicado: (2022)

The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
por: Kalra, Anjali, et al.
Publicado: (2023)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

Value and Financial Toxicity of New Cancer Drugs
por: Wickham, Rita J.
Publicado: (2016)

The crippling financial toxicity of cancer in the United States
por: Collado, Loren, et al.
Publicado: (2019)

Mitigating the Morbidity of Financial Toxicity in Cancer Care
por: Shankaran, Veena
Publicado: (2021)

Redefine the Role of Proton Beam Therapy for the Locally-Advanced Non-Small Cell Lung Cancer Assisting the Reduction of Acute Hematologic Toxicity
por: Cao, Xi, et al.
Publicado: (2022)

Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era
por: Jennane, Selim, et al.
Publicado: (2022)

Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
por: Hernandez, J. Javier, et al.
Publicado: (2017)

Modulators of radiation-induced cardiopulmonary toxicities for non-small cell lung cancer: Integrated cytokines, single nucleotide variants, and HBP systems imaging
por: Mukai-Sasaki, Yuki, et al.
Publicado: (2022)

Cardiovascular Toxicities from Systemic Breast Cancer Therapy
por: Guo, Shuang, et al.
Publicado: (2014)

Breast Cancer Survivorship, Quality of Life, and Late Toxicities
por: Nardin, Simone, et al.
Publicado: (2020)

Editorial: Adverse and Toxic Effects of Childhood Cancer Treatments
por: Ruggiero, Antonio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mc2ouauhm22a6dcbdt1a212g2r